In its Q4 earnings call to investors on February 25, vaccine developer Vaxcyte expressed optimism about its VAX-31 invasive pneumococcal disease (IPD) vaccine program and discussed the company’s ...

The world has reached another mile marker on the long and arduous road to eliminating human immunodeficiency virus (HIV) as a public-health threat. In June 2021, United Nations (UN) member states ...

At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...

Zuwei Jin, VP of Business Development at LISURE explains the advantages of the M++ system at BioProcess International US West 2025 in San Diego, CA. M++ is a pilot-scale modular benchtop system that ...

Figure 1A: Antibody–drug conjugate (ADC) structure and delivery pathways; linker chemistry determines the mechanism by which cytotoxin release occurs. This schematic shows a monoclonal antibody (MAb) ...

Under the terms of the agreement, Boehringer’s ADC arm NBE Therapeutics (acquired for €1.18 billion ($1.20 billion) in 2020) will use Synaffix’s GlycoConnect, HydraSpace, and toxSYN technologies for ...

In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US ...

In the 24th year of this millennium, the biopharma sector navigated seismic shifts, from legislative challenges and technological advancements to restructuring and landmark acquisitions. Together, ...

Explore the latest news and expert commentary on Event Videos, brought to you by the editors of BioProcess International.

Explore the latest news and expert commentary on Pre-Clinical & Clinical Trials, brought to you by the editors of BioProcess International ...

This webcast features: Jared Isaac, PhD, Sr. Scientist, Chromatography and Mass Spectrometry, Cygnus Technologies Next-generation recombinant vaccines and gene therapy products require clinical and ...

A significant challenge for TFF operators is an overreliance on vessel concentration estimates and upfront calculations, instead of real-time concentration data. In an attempt to maintain accuracies, ...